113 related articles for article (PubMed ID: 12410758)
1. Progesterone: a novel adjunct to intravesical chemotherapy.
Lewin J; Cooper A; Birch B
BJU Int; 2002 Nov; 90(7):736-41. PubMed ID: 12410758
[TBL] [Abstract][Full Text] [Related]
2. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
[TBL] [Abstract][Full Text] [Related]
3. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
[TBL] [Abstract][Full Text] [Related]
4. Estramustine reversal of resistance to intravesical epirubicin chemotherapy.
Jennings AM; Solomon LZ; Sharpe P; Hayes MC; Cooper AJ; Birch BR
Eur Urol; 1999 Apr; 35(4):327-35. PubMed ID: 10087397
[TBL] [Abstract][Full Text] [Related]
5. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
[TBL] [Abstract][Full Text] [Related]
6. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
Duffy PM; Hayes MC; Gatrell SK; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):824-9. PubMed ID: 8705215
[TBL] [Abstract][Full Text] [Related]
7. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Pu YS; Hsieh TS; Cheng AL; Tseng NF; Su IJ; Hsieh CY; Lai MK; Tsai TC
Br J Urol; 1996 Jan; 77(1):76-85. PubMed ID: 8653321
[TBL] [Abstract][Full Text] [Related]
8. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
Duffy PM; Hayes MC; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):819-23. PubMed ID: 8705214
[TBL] [Abstract][Full Text] [Related]
9. Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
Speers AG; Lwaleed BA; Featherstone JM; Sallis BJ; Cooper AJ
J Clin Pathol; 2006 Sep; 59(9):912-5. PubMed ID: 16556663
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
[TBL] [Abstract][Full Text] [Related]
11. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1).
Hayes MC; Birch BR; Cooper AJ; Primrose JN
BJU Int; 2001 Feb; 87(3):245-50. PubMed ID: 11167651
[TBL] [Abstract][Full Text] [Related]
12. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
13. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Speers AG; Lwaleed BA; Featherstone JM; Cooper AJ
J Urol; 2007 Nov; 178(5):2171-5. PubMed ID: 17870115
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-energy shock wave therapy on intravesical epirubicin delivery in a rat model of bladder cancer.
Elkashef A; Barakat N; Khater SM; Awadalla A; Belal F; El-Assmy AM; Sheir KZ; Shokeir AA
BJU Int; 2021 Jan; 127(1):80-89. PubMed ID: 32654305
[TBL] [Abstract][Full Text] [Related]
16. Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Popert RJ; Masters JR; Coptcoat M; Zupi G
Urol Res; 1995; 22(6):367-72. PubMed ID: 7740656
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
18. A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.
Liu CW; Wu YT; Lin KJ; Yu TJ; Kuo YL; Chang LC
Molecules; 2016 Jun; 21(6):. PubMed ID: 27258243
[TBL] [Abstract][Full Text] [Related]
19. Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.
Adigbli DK; Wilson DG; Farooqui N; Sousi E; Risley P; Taylor I; Macrobert AJ; Loizidou M
Br J Cancer; 2007 Aug; 97(4):502-12. PubMed ID: 17667930
[TBL] [Abstract][Full Text] [Related]
20. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro.
Lo YL; Wang W
Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
